

# Leishmaniasis Country Profile Generator

## User Manual

The Leishmaniasis Country Profile Generator, from now LCPG, retrieves country data from several sources for a specific year and puts it in an HTML country profile format ready to print in PDF.

## Table of Contents

|  |          |
|--|----------|
| <b>1. METADATA AND PERMISSIONS REQUIREMENTS.....</b>                 | <b>2</b> |
| <b>2. GENERATING A COUNTRY PROFILE.....</b>                          | <b>3</b> |
| 2.1 CONFIGURATION PANEL .....  | 4        |
| 2.1.1 General.....   | 4        |
| 2.2.2 Maps.....  | 5        |
| 2.2.3 Footnotes.....   | 6        |
| 2.2 COUNTRY PROFILE.....   | 7        |
| 2.2.1 Text to update before printing.....                            | 7        |
| 2.2.2 Edit elements in the CP.....                                   | 7        |
| 2.2.3 Footnote elements in the CP .....                              | 7        |
| 2.2.4 Arrange maps and charts .....                                  | 8        |
| 2.2.5 Printing the CP or saving it as PDF.....                       | 8        |
| <b>3. SOURCE OF INFORMATION IN COUNTRY PROFILE SECTIONS.....</b>     | <b>9</b> |
| 3.1 COUNTRY GENERAL INFORMATION SECTION.....                         | 9        |
| 3.2 EPIDEMIOLOGY SECTION .....                                       | 11       |
| 3.3 MONTHLY DISTRIBUTION OF NEW CASES JANUARY-DECEMBER SECTION ..... | 14       |
| 3.4 MAPS SECTION .....   | 15       |
| 3.5 CONTROL AND SURVEILLANCE SECTION .....                           | 16       |
| 3.6 DIAGNOSIS SECTION .....  | 17       |
| 3.7 TREATMENT AND MEDICINES AND TREATMENT OUTCOME SECTION.....       | 19       |


# 1. Metadata and permissions requirements

LCPG and the user using it need metadata (and eventually) data read access to the following metadata:

| Type           | ID          | Name   | Comments  |
|----------------|-------------|--|---|
| program        | w9hSFsNr3Vh | CL_cases_by provenance   |   |
| program        | NVUljZlakuO | Footnotes for Report Generator RG_                               | Needs to be assigned to the country               |
| program        | Jd8gnElt8uT | Leishmaniasis endemicity   | Needs to be assigned to the country               |
| program        | i5JSf4ffFI2 | VL_cases_by provenance   |   |
| dataSet        | Uc3j0vpsfSB | Cutaneous Leishmaniasis - ACL/ZCL - Detailed aggregated - Annual |   |
| dataSet        | Sn0dExPzQqW | Cutaneous Leishmaniasis - ACL/ZCL - Simple aggregated - Annual   |   |
| dataSet        | tnek2Ljfulm | Cutaneous Leishmaniasis - Detailed aggregated - Annual           |   |
| dataSet        | zna8KFLMXn4 | Cutaneous Leishmaniasis - Simple aggregated - Annual             |   |
| dataSet        | NKWbkXyfO5F | General information  | Needs to be assigned to the country               |
| dataSet        | p0NhulUoeST | GHO indicators for NTDs  | Needs to be assigned to the country               |
| dataSet        | fdBM4sWSuPR | Visceral Leishmaniasis - Detailed aggregated - Annual            |   |
| dataSet        | SHw2zOysJ1R | Visceral Leishmaniasis - Simple aggregated - Annual              |   |
| sqlViews       | mejVo59hWs  | categoryOptionCombos in DS                                       |   |
| sqlViews       | oQdlVqkVlxC | data elements in dataSet   |   |
| sqlViews       | lrawAndH02Y | data elements used in program                                    |   |
| legendSet      | clwSlrqvmMx | ACL Incidence  |   |
| legendSet      | TnU2O8YxH51 | CL Incidence   |   |
| legendSet      | gUOjExXros1 | VL Incidence   |   |
| legendSet      | TbrqpLWzLS8 | ZCL Incidence  |   |
| indicatorGroup | nozEoB0uRq9 | NTD_Leish_CP_INC_charts_IG                                       | It doesn't need the IG itself but its indicators. |
| indicatorGroup | VvTNYst2QCW | NTD_Leish_CP_maps_IG   | It doesn't need the IG itself but its indicators. |
| indicatorGroup | KUdeVRtIK45 | NTD_Leish_CP_popAtRisk_IG  | It doesn't need the IG itself but its indicators. |
| indicatorGroup | Wp7ZgcxoAwM | NTD_LSH_EPI_NEW_UNUS_IG  | It doesn't need the IG itself but its indicators. |
| indicatorGroup | OxgkCeNyVVm | NTD_LSH_TREAT_completed_IG                                       | It doesn't need the IG itself but its indicators. |
| indicatorGroup | jCYF44Wq3r7 | NTD_LSH_SCREEN_passive_IG  | It doesn't need the IG itself but its indicators. |

## 2. Generating a country profile

Look for the app called “Leishmaniasis Country Profile Generator” in the apps bar of the WIDP instance.



A form box like the following will appear

### Generate Country Profile

Year

Country

Start preparing CP

### Generate Country Profile

Year

Country

People's Democratic Republic of Algeria  
Republic of Albania

Start preparing CP

Start typing a year and a country. Once it starts appearing in the list, select it. This selection is needed, otherwise, the system won't take in account the text you typed.

The LCPG has two main sections: The configuration panel and the country profile itself.

Configuration Area - Wort be printed  
Instructions : Left click to add a footnote number  
Right click to edit an element.

General Maps Footnotes

Leishmaniasis types to show:

☒ VL ☐ CL ☒ AZCL ☒ ZCL ☐ PKDL ☒ MCL

Leishmaniasis types to show in monthly table:

☒ VL ☐ CL ☐ VL (previous year) ☐ CL (previous year) ☒ AZCL ☒ ZCL

☐ ACL (previous year) ☐ ZCL (previous year)

Graphs to show:

☐ CL monthly ☒ AZCL monthly ☒ VL monthly

☐ CL yearly ☒ AZCL yearly ☒ VL yearly

2nd sub-national administ...

World Health Organization

Leishmaniasis People's Democratic Republic of Algeria 2017  
Published in July 2019

Country General Information

|                   |                     |  |              |
|-------------------|---------------------|--|--------------|
| Total population: | 10 000 000          | Age group <15/> 14 years, %:                                     | 40% / 60%    |
| Gender (% F/M):   | 25.5% / 24.5%       | Life expectancy at birth in years (F/M):                         | 75 / 68      |
| GDP (PPP int \$): | 5000                | Number of 2nd sub-national administrative level divisions, name: | 1493, Abadla |
| Income status:    | Lower middle income |  |              |

Epidemiology

|  |    |     |     |     |
|--|----|-----|-----|-----|
|  | VL | ACL | ZCL | MCL |
|--|----|-----|-----|-----|

Endemicity status:

Configuration panel

Country profile

## 2.1 Configuration panel

In this panel you can configure which elements are showing in the CP and how. It has three tabs: General, to manage which types of the disease will appear in the tables, the graphs and the subnational level taken in account; maps to configure maps, legends and “notas bene”; and Footnotes, to manage which footnotes will appear in the CP.

### 2.1.1 General

The screenshot shows the 'General' tab of a configuration panel. At the top, there are three tabs: 'General' (selected), 'Maps', and 'Footnotes'. Below the tabs, there are three main sections:

- Leishmaniasis types to show:** A row of checkboxes for VL (checked), CL, ACL, ZCL, PKDL, and MCL.
- Leishmaniasis types to show in monthly table:** A row of checkboxes for VL (checked), VL (previous year), CL, CL (previous year), ACL, ACL (previous year), ZCL, and ZCL (previous year).
- Graphs to show:** A row of checkboxes for CL monthly, AZCL monthly, VL monthly (checked), CL yearly, AZCL yearly, and VL yearly (checked).

At the bottom, there is a dropdown menu labeled '1st sub-national administr...' and a checkbox labeled 'recalculate maps to this level' which is checked.

Leishmaniasis types to show are checked if, at least, one leishmaniasis dataset of this type (VL, CL or ACL/ZCL) is assigned to the country. PKDL and MCL are unchecked by default.

The behavior is the same in the monthly table checkboxes except for previous years, whose checkboxes are by default unchecked.

The graphs checkboxes follow also the same logic.

The subnational level dropdown menu is set, by default, to the first subnational level. Changing it to 2<sup>nd</sup> or 3<sup>rd</sup> subnational level will update:

- The “Number of endemic X sub-national...” row text-and-value in the Country General Information section.
- The “Number of endemic X sub-national...” row text-and-value in the Epidemiology section.
- All the maps if the “recalculate maps to this level” checkbox is checked.

## 2.2.2 Maps

As in the previous tab, the maps checkboxes follow the same logic of the previous other checkboxes.

The screenshot shows a configuration window with three tabs: 'General', 'Maps' (selected), and 'Footnotes'. The 'Maps' tab contains two main sections: 'Maps to show' and 'Configure map'.

**Maps to show:** This section has four checkboxes: 'VL incidence' (checked), 'CL incidence', 'ACL incidence', and 'ZCL incidence'.

**Configure map:** This section is divided into two columns.

- Left Column:**
  - 'Select a Map': A dropdown menu.
  - 'OrgUnit levels: WHO Member States - Level 1': A text label followed by a range slider.
  - 'OSM Light': A dropdown menu.
  - 'Opacity:': A slider set to 80.
  - 'Height:': A slider set to 315.
  - 'Width:': A slider set to 420.
  - 'Update Map': A button at the bottom.
- Right Column:**
  - 'Select a Legend': A dropdown menu.
  - 'Font size:': A text input field.
  - 'Update Legend': A button.
  - 'Resize Nota Bene for Maps:': A toggle switch set to 'Disabled'.
  - 'Resize Nota Bene:': A toggle switch set to 'Disabled'.

To update a map, select a map name on the dropdown. Select the deepest subnational level you want to see drawn in the map. You can select also the background layout, the opacity, the height and the width. Click “Update Map” once you finished the configuration.

You can relocate and resize the legend within the map. To do that, select a legend on the right dropdown menu. You will see appear the legend at right. You can resize it, edit the text or select the corner where it will be shown. Click “Update Legend” to apply changes.

Size of the two “Nota Bene” in the CP are locked by default. You may enable this feature to adapt the size of the box to the content or the location. Remember putting them back to “disabled” once you have finished.

## 2.2.3 Footnotes

General

Maps

Footnotes

Stored footnotes

Defined as "In this reporting period, an area at the 3rd sub-national administrative level reporting cases for the first time ever"

Defined as "Number of people living in 3rd sub-national administrative level endemic areas"

Defined as "In this reporting period, an area at the 2nd sub-national administrative level reporting cases for the first time ever"

Defined as "Number of people living in 2nd sub-national administrative level endemic areas"

Defined as "In this reporting period,

Footnotes page 1

1 Defined as "In this reporting period, an area at the 3rd sub-national administrative level reporting cases for the first time ever"

2 Defined as "Number of people living in 3rd sub-national administrative level endemic areas"

3 Relapse in this country is defined as: "a patient who experiences recurrence of VL symptoms with parasitological confirmation at any time point after initial cure"

Footnotes page 2

4 Failure in this country is defined as: "signs and symptoms persist or recur during treatment or up to initial treatment outcome assessment"

In this section you organize the footnotes stored in and got from the footnote program.

To move one footnote from one page to another or to remove from the CP, just drag and drop it in the correct box. You can reorder them within the box. The footnote index will be accordingly updated. However, the index you put in the CP text are not "linked" to these footnotes: It's up to you to make sure the reference and the index match.

## 2.2 Country profile

### 2.2.1 Texts to update before printing

Two texts in CP are generated but must be verified before printing. Those text are highlighted in red and, as described in 2.2.2 section, can be modified and its color changed to black. The texts are:

Name of the division levels: The system, takes, as example, the first subdivision level found, but this text should be updated to its specific category name (region, district, department, upazilla... etc).


|  |               |
|--|---------------|
| Age group <15/> 14 years, %:                                     | - / -         |
| Life expectancy at birth in years (F/M):                         | N/A /<br>N/A  |
| Number of 1st sub-national administrative level divisions, name: | 6,<br>Central |

Title on maps: The text in red is automatically changed when you check or uncheck the maps, checkboxes. Just, verify the title is correct and change the color to blue.

Distribution of VL and CL cases per 10 000 population

### 2.2.2 Edit elements in the CP

You can edit almost any text in the CP. To do that, just right click on the element and an edit field box will pop up. You can change the text, color, size, text style, add hyperlinks, etc.



### 2.2.3 Footnote elements in the CP



You can footnote almost any element of the CP by left clicking on the element. A footnote index (1 for first clicked element) will be added to the element. The next element will be footnoted with the number "2" and so on. If you want to remove a footnote index, just left click again on it. It's better to remove all higher footnote indexes first, to keep a logic sequence of indexes.

Was there any outbreak?<sup>1</sup>  
Number of new foci:<sup>2</sup>  
N/A not applicable

## 2.2.4 Arrange maps and charts

Charts and maps can be moved by clicking on them and moving the mouse to the desired location.

In addition, maps can be zoomed in and its content moved up, down, left or right. However, they cannot be zoomed out for the instance. If you need to reset a map, just go to the maps section in the configuration zone, select the map and click on “Update map”.



## 2.2.5 Printing the CP or saving it as PDF

In order to generate the PDF version of the CP, click ctrl+P. You can adjust the final with the parameters: paper size (A4) scale (normally 100%), margins (minimum or custom). Select your printer or the option “Save as PDF”.

The screenshot shows the CP (Country Profile) interface for the Federal Democratic Republic of Nepal. The top section displays country general information, including total population, GDP, and life expectancy. The middle section displays epidemiology data, including the number of new cases, incidence rate, and population at risk. The bottom section displays a chart showing the number of new (primary) VL cases reported by month in 2016 and 2017. A print dialog is open on the right side, showing settings for paper size (A4), pages per sheet (1), margins (Custom), quality (120 dpi), scale (Custom), and options (Headers and footers, Background graphics). The print button is highlighted.



### 3. Source of information in country profile sections

#### 3.1 Country general information section

|    |                             |                     |    |   |
|----|-----------------------------|---------------------|----|---|
| B1 | COUNTRY GENERAL INFORMATION |                     |    |   |
| B2 | Total population:           | 41,320,000          | B5 | Age group <15/> 14 years, %: 0% / 0%  |
| B3 | Gender (% , F/M):           | 0% / 0%             | B6 | Life expectancy at birth in years (F/M): 75 / 68                              |
| B4 | GDP (PPP int \$):           | 5000                | B7 | Number of 2nd sub-national administrative level divisions, name: 1493, Abadla |
|    | Income status:              | Lower middle income |    |   |

| CODE                   | DataSet / Program     | DataElement / Indicator             | CatCombos / comments  |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
|------------------------|-----------------------|-------------------------------------|---|----|------|----|------------------|-------------|------------------|-------------|-----------------|-------------|--------------------|-------------|--------------------|-------------|--------------------|-------------|--------------------|-------------|--------------------|-------------|--------------------|-------------|--------------------|-------------|--------------------|-------------|--------------------|-------------|--------------------|-------------|--------------------|-------------|--------------------|-------------|--------------------|-------------|--------------------|-------------|--------------------|-------------|--------------------|-------------|--------------------|-------------|------------------------|-------------|
| B1                     | DS_GeneralInformation | GEN_UN_WPP_Pop_Tot_1000 * 1000      | It shows “No data” if no data value found.  |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| B2                     | DS_GeneralInformation | GEN_UN_WPP_Pop_Tot_AgeSex_1000 / B1 | <table><tr><td>name</td><td>id</td></tr><tr><td>Under 5y, Female</td><td>o7NkWI5xFuS</td></tr><tr><td>5 to 9 y, Female</td><td>xodN5e1QCp6</td></tr><tr><td>10-14yr, Female</td><td>oic7kU2uVtJ</td></tr><tr><td>15 to 19 y, Female</td><td>adEelGXyPln</td></tr><tr><td>20 to 24 y, Female</td><td>SobJ4FGuBRA</td></tr><tr><td>25 to 29 y, Female</td><td>qdWOGC6bbBi</td></tr><tr><td>30 to 34 y, Female</td><td>IVFKF7NzjJa</td></tr><tr><td>35 to 39 y, Female</td><td>Jkrg1KI25AV</td></tr><tr><td>40 to 44 y, Female</td><td>i6rBoDsk4LE</td></tr><tr><td>45 to 49 y, Female</td><td>irBgvZTT9zq</td></tr><tr><td>50 to 54 y, Female</td><td>B2cv93OdJpl</td></tr><tr><td>55 to 59 y, Female</td><td>nJEkgZS74Tt</td></tr><tr><td>60 to 64 y, Female</td><td>RJDdLqVGxu8</td></tr><tr><td>65 to 69 y, Female</td><td>ECle1XHoHZ2</td></tr><tr><td>70 to 74 y, Female</td><td>Gh29gSpSYpp</td></tr><tr><td>75 to 79 y, Female</td><td>zvECz1sg3sj</td></tr><tr><td>80 to 84 y, Female</td><td>BO8BiFA6WZo</td></tr><tr><td>85 to 89 y, Female</td><td>hI8wdaiRHaS</td></tr><tr><td>90 to 94 y, Female</td><td>kH3O17Sezfp</td></tr><tr><td>95 to 99 y, Female</td><td>nHBTtdVMe7I</td></tr><tr><td>100 y and over, Female</td><td>gkeN62eQISA</td></tr></table> |    | name | id | Under 5y, Female | o7NkWI5xFuS | 5 to 9 y, Female | xodN5e1QCp6 | 10-14yr, Female | oic7kU2uVtJ | 15 to 19 y, Female | adEelGXyPln | 20 to 24 y, Female | SobJ4FGuBRA | 25 to 29 y, Female | qdWOGC6bbBi | 30 to 34 y, Female | IVFKF7NzjJa | 35 to 39 y, Female | Jkrg1KI25AV | 40 to 44 y, Female | i6rBoDsk4LE | 45 to 49 y, Female | irBgvZTT9zq | 50 to 54 y, Female | B2cv93OdJpl | 55 to 59 y, Female | nJEkgZS74Tt | 60 to 64 y, Female | RJDdLqVGxu8 | 65 to 69 y, Female | ECle1XHoHZ2 | 70 to 74 y, Female | Gh29gSpSYpp | 75 to 79 y, Female | zvECz1sg3sj | 80 to 84 y, Female | BO8BiFA6WZo | 85 to 89 y, Female | hI8wdaiRHaS | 90 to 94 y, Female | kH3O17Sezfp | 95 to 99 y, Female | nHBTtdVMe7I | 100 y and over, Female | gkeN62eQISA |
|                        |                       |                                     | name  | id |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| Under 5y, Female       | o7NkWI5xFuS           |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| 5 to 9 y, Female       | xodN5e1QCp6           |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| 10-14yr, Female        | oic7kU2uVtJ           |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| 15 to 19 y, Female     | adEelGXyPln           |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| 20 to 24 y, Female     | SobJ4FGuBRA           |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| 25 to 29 y, Female     | qdWOGC6bbBi           |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| 30 to 34 y, Female     | IVFKF7NzjJa           |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| 35 to 39 y, Female     | Jkrg1KI25AV           |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| 40 to 44 y, Female     | i6rBoDsk4LE           |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| 45 to 49 y, Female     | irBgvZTT9zq           |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| 50 to 54 y, Female     | B2cv93OdJpl           |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| 55 to 59 y, Female     | nJEkgZS74Tt           |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| 60 to 64 y, Female     | RJDdLqVGxu8           |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| 65 to 69 y, Female     | ECle1XHoHZ2           |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| 70 to 74 y, Female     | Gh29gSpSYpp           |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| 75 to 79 y, Female     | zvECz1sg3sj           |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| 80 to 84 y, Female     | BO8BiFA6WZo           |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| 85 to 89 y, Female     | hI8wdaiRHaS           |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| 90 to 94 y, Female     | kH3O17Sezfp           |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| 95 to 99 y, Female     | nHBTtdVMe7I           |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| 100 y and over, Female | gkeN62eQISA           |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
|                        |                       |                                     | <table><tr><td>name</td><td>id</td></tr><tr><td>Under 5y, Male</td><td>gWsMIgPOsZy</td></tr><tr><td>5 to 9 y, Male</td><td>lptUC1gVg8o</td></tr><tr><td>10-14yr, Male</td><td>o8dMMqNDctr</td></tr><tr><td>15 to 19 y, Male</td><td>xdAhLef7xG4</td></tr><tr><td>20 to 24 y, Male</td><td>ZYAx6PjJ2ZM</td></tr><tr><td>25 to 29 y, Male</td><td>AJkBK9XBytM</td></tr><tr><td>30 to 34 y, Male</td><td>xsUkVSOPK0u</td></tr><tr><td>35 to 39 y, Male</td><td>VwZsMBUBdR1</td></tr><tr><td>40 to 44 y, Male</td><td>XucrdYEMOE7</td></tr><tr><td>45 to 49 y, Male</td><td>BvCWylwlqa8</td></tr><tr><td>50 to 54 y, Male</td><td>RwwDYedBcDI</td></tr><tr><td>55 to 59 y, Male</td><td>xaMRyDOevEu</td></tr><tr><td>60 to 64 y, Male</td><td>Ss3gp5wAYOQ</td></tr><tr><td>65 to 69 y, Male</td><td>a2dH289sMou</td></tr><tr><td>70 to 74 y, Male</td><td>COVIpje6ADR</td></tr><tr><td>75 to 79 y, Male</td><td>MKDyDGdryXB</td></tr><tr><td>80 to 84 y, Male</td><td>Bpl46BM32FB</td></tr><tr><td>85 to 89 y, Male</td><td>avCYQARWeei</td></tr><tr><td>90 to 94 y, Male</td><td>PKDfpYDkyoy</td></tr><tr><td>95 to 99 y, Male</td><td>kXo51Sydk1t</td></tr><tr><td>100 y and over, Male</td><td>ttAEJltz1yh</td></tr></table>   |    | name | id | Under 5y, Male   | gWsMIgPOsZy | 5 to 9 y, Male   | lptUC1gVg8o | 10-14yr, Male   | o8dMMqNDctr | 15 to 19 y, Male   | xdAhLef7xG4 | 20 to 24 y, Male   | ZYAx6PjJ2ZM | 25 to 29 y, Male   | AJkBK9XBytM | 30 to 34 y, Male   | xsUkVSOPK0u | 35 to 39 y, Male   | VwZsMBUBdR1 | 40 to 44 y, Male   | XucrdYEMOE7 | 45 to 49 y, Male   | BvCWylwlqa8 | 50 to 54 y, Male   | RwwDYedBcDI | 55 to 59 y, Male   | xaMRyDOevEu | 60 to 64 y, Male   | Ss3gp5wAYOQ | 65 to 69 y, Male   | a2dH289sMou | 70 to 74 y, Male   | COVIpje6ADR | 75 to 79 y, Male   | MKDyDGdryXB | 80 to 84 y, Male   | Bpl46BM32FB | 85 to 89 y, Male   | avCYQARWeei | 90 to 94 y, Male   | PKDfpYDkyoy | 95 to 99 y, Male   | kXo51Sydk1t | 100 y and over, Male   | ttAEJltz1yh |
| name                   | id                    |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| Under 5y, Male         | gWsMIgPOsZy           |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| 5 to 9 y, Male         | lptUC1gVg8o           |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| 10-14yr, Male          | o8dMMqNDctr           |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| 15 to 19 y, Male       | xdAhLef7xG4           |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| 20 to 24 y, Male       | ZYAx6PjJ2ZM           |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| 25 to 29 y, Male       | AJkBK9XBytM           |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| 30 to 34 y, Male       | xsUkVSOPK0u           |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| 35 to 39 y, Male       | VwZsMBUBdR1           |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| 40 to 44 y, Male       | XucrdYEMOE7           |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| 45 to 49 y, Male       | BvCWylwlqa8           |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| 50 to 54 y, Male       | RwwDYedBcDI           |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| 55 to 59 y, Male       | xaMRyDOevEu           |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| 60 to 64 y, Male       | Ss3gp5wAYOQ           |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| 65 to 69 y, Male       | a2dH289sMou           |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| 70 to 74 y, Male       | COVIpje6ADR           |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| 75 to 79 y, Male       | MKDyDGdryXB           |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| 80 to 84 y, Male       | Bpl46BM32FB           |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| 85 to 89 y, Male       | avCYQARWeei           |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| 90 to 94 y, Male       | PKDfpYDkyoy           |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| 95 to 99 y, Male       | kXo51Sydk1t           |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| 100 y and over, Male   | ttAEJltz1yh           |                                     |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| B3                     | DS_GeneralInformation | NY.GDP.PCAP.PP.CD                   |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |
| B4                     | DS_GeneralInformation | GEN WB IncomeGroup                  |   |    |      |    |                  |             |                  |             |                 |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                    |             |                        |             |

|    |   |  |  |  |
|----|---|--|--|--|
| B5 | DS_GeneralInformation   | GEN_UN_WPP_Pop_Tot_AgeSex_1000                                 | As B2, but also those Gender Unknown.<br>Left: Under 5y, 5 to 9 y, 10-14yr<br>Right: All the others. |  |
| B6 | DS_GeneralInformation   | GEN_UN_WPP_LifeExpBirth_Female<br>GEN_UN_WPP_LifeExpBirth_Male |  |  |
| B7 | Number of subdivisions in the orgUnitTree for the current country at the selected level. The name is the first occurrence found in the orgUnitTree. |  |  |  |

### 3.2 Epidemiology section

| EPIDEMIOLOGY  |  |                    |                    |                  |                  |         |                          |
|---|--|--------------------|--------------------|------------------|------------------|---------|--------------------------|
|   | VL   | CL                 | ACL                | ZCL              | PKDL MCL         |         |                          |
| C1  | Endemicity status:   | Non endemic        | Previously endemic | Endemic          | Endemic          | Error!  | Error!                   |
| C2  | Number of new cases (incidence):                                       | 25                 | 15                 | 100              | 50               | No data | 105                      |
| C3  | Number of relapse cases:   | No data            | 1                  | No data          | No data          | N/A     | N/A                      |
| C4  | Total number of cases:   | 25                 | 18                 | 100              | 50               | No data | 105                      |
| C5  | Imported cases (#, %):   | No data, No data   | 21, 33%            | No data, No data | No data, No data | N/A     | N/A                      |
| C6  | Gender distribution (%F):  | No data            | 33%                | No data          | No data          | No data | 99%                      |
| C7  | Age group distribution (% , <5/5-14/>14):                              | No data            | (43, 47, 10)       | No data          | No data          | No data | (100, No data, No data). |
| C8  | Incidence rate (cases/10 000 population in endemic areas):             | 0.01               | 0                  | -                | -                | N/A     | N/A                      |
| C9  | Number of endemic 1st sub-national administrative level divisions (n): | 9                  | 47                 | No data          | No data          | N/A     | N/A                      |
| C10   | Population at risk (% , n/total):                                      | 0% 1800 / 41320000 | 0% 9200 / 41320000 | 0% 0 / 41320000  | 0% 0 / 41320000  | N/A     | N/A                      |
| C11   | Was there any outbreak?  | No data            | Yes                | No data          | No data          | N/A     | N/A                      |
| C12   | Number of new foci:  | No data            | 987                | No data          | No data          | N/A     | N/A                      |
| N/A not applicable    VL = visceral leishmaniasis    CL = cutaneous leishmaniasis    ACL = anthroponotic cutaneous leishmaniasis    ZCL = zoonotic cutaneous leishmaniasis    PKDL = post-kala-azar dermal leishmaniasis    MCL = mucocutaneous leishmaniasis |  |                    |                    |                  |                  |         |                          |


See detailed descriptions on table on next page. Codes are used when possible. Names or names and UIDs otherwise.

| CODE | DataSet  | DataElement / Indicator  | CatCombos / Comments  |  |
|------|--|--|---|--|
| C1   | GHO_NTDs   | NTD_LEISHVEND<br>NTD_LEISHCEND<br>NTD_LEISHACEND<br>NTD_LEISHZCEND<br>NTD_LEISHMCEND<br>NTD_LEISHPKDLEND | -   | It replaces the numeric code (1,3 or 5) by "Endemic", "Previously endemic" or "Non endemic". It shows "Error!" if other code is found. |
| C2   | DS_VL_Detailed_Annual<br>DS_VL_Simple_Annual<br>GHO_NTDs                           | VL_EPI_Type  | New<br><br>(default for PKDL and MCL)   | It shows "No data" if no data found in the system.   |
|      | DS_CL_Detailed_Annual<br>DS_CL_Detailed_Monthly<br>DS_CL_Simple_Annual<br>GHO_NTDs | CL_EPI_Type<br>MCL_GEN_EPID_cases  |   |  |
|      | DS_ACL/ZCL_Detailed_Annual   | ACL_EPI_Type<br>ZCL_EPI_Type   |   |  |
|      | DS_VL_Detailed_Annual<br>DS_VL_Simple_Annual                                       | PKDL_GEN_EPID_cases  |   |  |
| C3   | *As C2 for each DE   | VL_EPI_Type<br>CL_EPI_Type<br>ACL_EPI_Type<br>ZCL_EPI_Type   | Relapse<br>(N/A for PKDL and MCL)   | It shows "No data" if no data found in the system.   |
| C4   | *As C2 for each DE   | VL_EPI_Type<br>CL_EPI_Type<br>ACL_EPI_Type<br>ZCL_EPI_Type<br>PKDL_GEN_EPID_cases<br>MCL_GEN_EPID_cases  | New<br>Relapse<br>Type unspecified<br>(default for PKDL and MCL)  | It shows "No data" if no data found in the system.   |
| C5   | DS_VL_Simple_Annual<br>DS_VL_Detailed_Annual                                       | VL_EPI_Type_Origin   | New, Autochthonous<br>Relapse, Autochthonous<br>Type unspecified, Autochthonous<br>New, Imported<br>Relapse, Imported<br>Type unspecified, Imported<br>New, Origin unknown<br>Relapse, Origin unknown<br>Type unspecified, Origin unknown<br><br>LCPG shows - instead XY% if it was not able to calculate percentage.   |  |
|      | DS_CL_Detailed_Annual<br>DS_CL_Detailed_Monthly<br>DS_CL_Simple_Annual             | CL_EPI_Type_Origin   |   |  |
|      | DS_ACL/ZCL_Detailed_Annual   | ACL_EPI_Type_Origin  |   |  |
|      |  | ZCL_EPI_Type_Origin  |   |  |
| C6   | DS_VL_Detailed_Annual  | VL_EPI_Type_Gender   | name="New, Female" id="TtoYCIvCBA3"<br>name="New, Gender Unknown" id="FaYhAikLX16"<br>name="New, Male" id="GpQZH8hC7jY"<br>name="Type unspecified, Female" id="wGED4K5Bs37"<br>name="Type unspecified, Gender Unknown" id="zkKbllarKWM"<br>name="Type unspecified, Male" id="aWWYWv6buzp"<br><br>LCPG shows - instead XY% if it was not able to calculate percentage. |  |
|      | DS_CL_Detailed_Monthly<br>DS_CL_Detailed_Annual                                    | CL_EPI_Type_Gender   |   |  |
|      | DS_ACL/ZCL_Detailed_Annual   | ACL_EPI_Type_Gender  |   |  |
|      |  | ZCL_EPI_Type_Gender  |   |  |
|      | DS_VL_Detailed_Annual  | PKDL_EPID_sex  | name="Female" id="V2LdgcGgFQt"<br>name="Gender Unknown" id="jNbFhhnUsQv"<br>name="Male" id="Z2hvpF7mhh7"  |  |
|      | DS_CL_Detailed_Monthly<br>DS_CL_Simple_Annual<br>DS_CL_Detailed_Annual             | MCL_EPID_sex   |   |  |
| C7   | DS_VL_Detailed_Annual  | VL_EPI_Type_Age  | name="New, 15 y and over" id="DDliBAHqwGV"<br>name="New, 5 to 14 y" id="mTyLqDjpQ5b"<br>name="New, Age Unknown" id="dVuOzmU4xbl"<br>name="New, Under 5y" id="hKq5WASZw8q"<br>name="Type unspecified, 15 y and over" id="UQMTeRPY2U0"<br>name="Type unspecified, 5 to 14 y" id="P6R9XEaqQbz"<br>name="Type unspecified, Age Unknown" id="nlbrdHlIMKh"                  |  |
|      | DS_CL_Detailed_Monthly<br>DS_CL_Detailed_Annual                                    | CL_EPI_Type_Age  |   |  |
|      | DS_ACL/ZCL_Detailed_Annual   | ACL_EPI_Type_Age   |   |  |
|      |  | ZCL_EPI_Type_Age   |   |  |

|     |  |  |  |   |
|-----|--|--|--|---|
|     |  |  | name="Type unspecified, Under 5y" id="rZwYGlqR8GG"   |   |
|     | DS_VL_Detailed_Annual                        | PKDL_EPID_age  | name="15 y and over" id="rN9ELJVdEpo"<br>name="5 to 14 y" id="moktBQGym51"<br>name="Age Unknown" id="gPGNI7bWhDB"<br>name="Under 5y" id="HDXcEOGT2s1"  |   |
|     | DS_CL_Detailed_Monthly                       | MCL_EPID_age   |  |   |
|     | DS_CL_Simple_Annual<br>DS_CL_Detailed_Annual |  |  |   |
| C8  | -  | NTD_LSH_VL_EPI_NEW_UNSI<br>NTD_LSH_CL_EPI_NEW_UNSI<br>NTD_LSH_ACL_EPI_NEW_UNSI<br>NTD_LSH_ZCL_EPI_NEW_UNSI<br><br>* 10000 / population at risk<br>(numerator at C10) | If population at risk is 0, the incidence text shows N/A.<br>N/A for PKDL and MCL.   |   |
| C9  | Leishmaniasis endemicity                     | DET_VL_endemicity_WHO<br>DET_CL_endemicity_WHO<br>DET_ACL_endemicity_WHO<br>DET_ZCL_endemicity_WHO   | Gets the count of orgUnits at the selected subnational level in <b>CODEHERE</b> having "1" as value for the dataElement and year.<br>N/A for PKDL and MCL.   |   |
| C10 | -  | VL_POP_AT_RISK_I<br>CL_POP_AT_RISK_I<br>ACL_POP_AT_RISK_I<br>ZCL_POP_AT_RISK_I   | Adds all the values at selected subnational level in <b>CODEHERE</b> . The indicator value is GEN_pop_Leish if the corresponding PI XXX_endemicity_WHO_factor1_PI equals 1. The indicator value is 0 otherwise.<br><br>LCPG shows - instead XY% if it was not able to calculate percentage.<br><br>N/A for PKDL and MCL. |   |
|     | DS_GeneralInformation                        | B1   | Total population is same value as B1   |   |
| C11 | DS_VL_Simple_Annual<br>DS_VL_Detailed_Annual | VL_GEN_EPID_outbreak   | default  | Converts the boolean value to Yes/No text.<br>N/A for PKDL and MCL. |
|     | DS_CL_Detailed_Annual<br>DS_CL_Simple_Annual | CL_GEN_EPID_outbreak   |  |   |
|     | DS_ACL/ZCL_Detailed_Annual                   | ACL_GEN_EPID_outbreak<br>ZCL_GEN_EPID_outbreak   |  |   |
| C12 | DS_VL_Simple_Annual<br>DS_VL_Detailed_Annual | VL_GEN_EPID_new focus  | default  | N/A for PKDL and MCL.   |
|     | DS_CL_Detailed_Annual<br>DS_CL_Simple_Annual | CL_GEN_EPID_new focus  |  |   |
|     | DS_ACL/ZCL_Detailed_Annual                   | ACL_GEN_EPID_new focus<br>ZCL_GEN_EPID_new focus   |  |   |

### 3.3 Monthly distribution of new cases January-December section

| Monthly distribution of new cases January-December |      |      |      |      |      |      |      |      |      |      |      |      |
|--|------|------|------|------|------|------|------|------|------|------|------|------|
|  | JAN  | FEB  | MAR  | APR  | MAY  | JUN  | JUL  | AUG  | SEP  | OCT  | NOV  | DEC  |
| D1 VL  |      |      |      |      |      |      |      |      |      |      |      |      |
| VL (previous year)                                 | 1909 | 1441 | 1441 | 1441 | 1441 | 1441 | 1441 | 1441 | 1441 | 1441 | 1441 | 1441 |
| D2 CL  | 323  | 473  | 439  | 445  | 552  | 593  | 412  | 417  | 451  | 445  | 443  | 421  |
| CL (previous year)                                 | 1661 | 1597 | 276  |      |      |      |      |      |      |      |      |      |
| D3 ACL   | 427  | 581  | 569  | 554  | 498  | 438  | 569  | 371  | 350  | 549  | 380  | 570  |
| ACL (previous year)                                | 1664 | 1865 | 101  |      |      |      |      |      |      |      |      |      |
| D4 ZCL   | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    |
| ZCL (previous year)                                | 2300 | 1794 | 122  |      |      |      |      |      |      |      |      |      |



| CODE | Program                | DataElement              |
|------|------------------------|--------------------------|
| D1   | VL_cases_by provenance | VL_cases_byProvenance_T  |
| D2   | CL_cases_by provenance | CL_cases_byProvenance_T  |
| D3   |                        | ACL_cases_byProvenance_T |
| D4   |                        | ZCL_cases_byProvenance_T |

#### Number of cases (D5)


| INDICATOR                 | Numerator  | den | Comments              |
|---------------------------|--|-----|-----------------------|
| NTD LSH VL EPI NEW UNS I  | VL EPI Type New + VL EPI Type Type unspecified   | 1   | indicatorType: number |
| NTD LSH CL EPI NEW UNS I  | CL EPI Type New + CL EPI Type Type unspecified   |     |                       |
| NTD LSH ACL EPI NEW UNS I | ACL EPI Type New + ACL EPI Type Type unspecified |     |                       |
| NTD LSH ZCL EPI NEW UNS I | ZCL EPI Type New + ZCL EPI Type Type unspecified |     |                       |

#### Incidence rates (D5)

| INDICATOR                  | Numerator                | denominator                    | Comments                        |
|----------------------------|--------------------------|--------------------------------|---------------------------------|
| IA VL EPI INC PopUN 10000  | VL_cases_byProvenance_T  | GEN_UN_WPP_Pop_Tot_1000 * 1000 | indicatorType: Per ten thousand |
| IA CL EPI INC PopUN 10000  | CL_cases_byProvenance_T  |                                |                                 |
| IA ACL EPI INC PopUN 10000 | ACL_cases_byProvenance_T |                                |                                 |
| IA ZCL EPI INC PopUN 10000 | ZCL_cases_byProvenance_T |                                |                                 |

### 3.4 Maps section

Distribution of VL/CL/ACL/ZCL cases per 10 000 population



The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.  
Map production: WHO/HTM/NTD/IDM

| INDICATOR                     | Numerator                | denominator                                   | Comments                                  |
|-------------------------------|--------------------------|---|---|
| VL EPI INC PopData LSH 10000  | VL cases byProvenance T  | GEN_pop_Leish<br>(In Population data dataset) | <b>indicatorType:</b><br>Per ten thousand |
| CL EPI INC PopData LSH 10000  | CL cases byProvenance T  |   |   |
| ACL EPI INC PopData LSH 10000 | ACL cases byProvenance T |   |   |
| ZCL EPI INC PopData LSH 10000 | ZCL cases byProvenance T |   |   |

| LEGENDSET name  | Legend Name      | startValue | endValue | Color   |
|---|------------------|------------|----------|---------|
| VL_INCIDENCE_LEGEND_0_10  | No case reported | 0.0        | 0.001    | #CCFFCC |
|   | 0<1              | 0.001      | 1.0      | #FFFFCC |
|   | [1-2.5]          | 1.0        | 2.5      | #FED976 |
|   | [2.5-10]         | 2.5        | 10.0     | #FC4E2A |
|   | ≥10              | 10.0       | 10000.0  | #800026 |
| CL_INCIDENCE_LEGEND_0_100<br>ACL_INCIDENCE_LEGEND_0_100<br>ZCL_INCIDENCE_LEGEND_0_100 | No case reported | 0.0        | 0.001    | #CCFFCC |
|   | 0<10             | 0.001      | 10.0     | #FFFFCC |
|   | [10-50]          | 10.0       | 50.0     | #FED976 |
|   | [50-100]         | 50.0       | 100.0    | #FC4E2A |
|   | ≥100             | 100.0      | 10000.0  | #800026 |

### 3.5 Control and surveillance section

| CONTROL AND SURVEILLANCE |   |                      |    |  |                   |
|--------------------------|---|----------------------|----|--|-------------------|
| G1                       | Year Leishmaniasis National Control Programme (LNCP) was established: | 2001                 | G5 | Year latest national guidelines (CL / VL):                 | No data / No data |
| G2                       | Type of surveillance (CL / VL):                                       | No data / Integrated | G6 | Is leishmaniasis notifiable (mandatory report)? (CL / VL): | No data / No data |
| G3                       | Is there a vector control programme?                                  | Yes                  | G7 | Is there a reservoir host control programme?               | Yes               |
| G4                       | Type of insecticide used for Indoor residual Spraying (IRS):          | 101                  | G8 | Number of leishmaniasis health facilities (CL / VL):       | No data / No data |

| CODE | DataSet  | DataElement / Indicator             | Comments  |
|------|--|-------------------------------------|---|
| G1   | DS_VL_Detailed_Annual<br>DS_CL_Detailed_Annual<br>DS_ACL/ZCL_Detailed_Annual | Leish_GEN_LNCP_year                 | It shows "No data" when no entry found in the system.   |
| G2   | DS_CL_Detailed_Annual  | CL_GEN_Surv_Type                    | Converts codes into texts:<br>1: Vertical<br>2: Integrated<br>7: Other<br>8: Non-applicable<br>9: Unknown |
|      | DS_VL_Detailed_Annual  | VL_GEN_Surv_Type                    |   |
| G3   | DS_CL_Detailed_Annual<br>DS_ACL/ZCL_Detailed_Annual<br>DS_VL_Detailed_Annual | Leish_GEN_VectorControl             | Converts codes into texts:<br>1: Yes<br>2: No<br>9: Unknown   |
| G4   |  | Leish_GEN_VectorControl_Insecticide | It shows "No data" when no entry found in the system.   |
| G5   | DS_ACL/ZCL_Detailed_Annual<br>DS_CL_Detailed_Annual                          | CL_GEN_Guidelines_year              | It shows "No data" when no entry found in the system.   |
|      | VL_GEN_Guidelines_year   | VL_GEN_Guidelines_year              |   |
| G6   | DS_CL_Detailed_Annual<br>DS_ACL/ZCL_Detailed_Annual                          | CL_GEN_Surv_Notif                   | Converts codes into texts:<br>1: Yes<br>2: No<br>9: Unknown   |
|      | DS_VL_Detailed_Annual  | VL_GEN_Surv_Notif                   |   |
| G7   | DS_CL_Detailed_Annual<br>DS_ACL/ZCL_Detailed_Annual<br>DS_VL_Detailed_Annual | Leish_GEN_ReservoirControl          | Converts codes into texts:<br>1: Yes<br>2: No<br>9: Unknown   |
| G8   | DS_CL_Detailed_Annual  | CL_GEN_Surv_HF                      | It shows "No data" when no entry found in the system.   |
|      |  | VL_GEN_Surv_HF                      |   |



### 3.6 Diagnosis section

| DIAGNOSIS  |  | VL               | CL      | ACL     | ZCL     | PKDL | MCL |
|--|--|------------------|---------|---------|---------|------|-----|
| H1   | Number of people screened actively for:  | No data          | No data | N/A     | N/A     | N/A  | N/A |
| H2   | Number of people screened passively for:                                       | No data          | N/A     | N/A     | N/A     | N/A  | N/A |
| H3   | VL cases diagnosed by RDT*<br>(%, RDT+/total VL cases):                        | 86% (216 / 252)  | N/A     | N/A     | N/A     | N/A  | N/A |
| H4   | Proportion of positive RDT*<br>(%, RDT+/total RDT):                            | 100% (216 / 216) | N/A     | N/A     | N/A     | N/A  | N/A |
| H5   | Cases diagnosed by direct exam<br>(parasitology) (%, # slides +/-total cases): | 15% (38 / 252)   | No data | N/A     | N/A     | N/A  | N/A |
| H6   | Proportion of positive slides<br>(%, # slides +/-total slides):                | 100% (38 / 38)   | No data | No data | No data | N/A  | N/A |
| H7   | Cases diagnosed clinically<br>(%, # clinical cases/total cases):               | 0% (0 / 252)     | No data | N/A     | N/A     | N/A  | N/A |
| H8   | Percentage of cases with HIV-VL coinfection:                                   | 0% (0 / 252)     | N/A     | N/A     | N/A     | N/A  | N/A |
| N/A not applicable<br>VL = visceral leishmaniasis<br>CL = cutaneous leishmaniasis<br>ACL = anthroponotic cutaneous leishmaniasis<br>ZCL = zoonotic cutaneous leishmaniasis<br>PKDL = post-kala-azar dermal leishmaniasis<br>MCL = mucocutaneous leishmaniasis<br>HIV = human immunodeficiency virus<br>* These indicators apply only for primary VL cases<br>RDT = rapid diagnostic test |  |                  |         |         |         |      |     |

| CODE | DataSet                    | DataElement / Indicator                                      | CatCombos / Comments  |   |
|------|----------------------------|--|---|---|
| H1   | DS_VL_Detailed_Annual      | VL_SCREEN_active   | -   | N/A for PKDL and MCL  |
|      | DS_CL_Detailed_Monthly     | CL_SCREEN_active   |   |   |
|      | DS_CL_Detailed_Annual      |  |   |   |
|      | DS_ACL/ZCL_Detailed_Annual | ACL_SCREEN_active<br>ZCL_SCREEN_active                       |   |   |
| H2   | DS_VL_Detailed_Annual      | NTD_LSH_VL_SCREEN_passive_I                                  | -   | The related DE is assigned to the dataset but it's not in the form!                               |
|      | DS_CL_Detailed_Monthly     | NTD_LSH_CL_SCREEN_passive_I                                  | -   | The related DE is not assigned to the dataset!  |
|      | DS_CL_Detailed_Annual      |  | -   |   |
|      | DS_ACL/ZCL_Detailed_Annual | NTD_LSH_ACL_SCREEN_passive_I<br>NTD_LSH_ZCL_SCREEN_passive_I | -   | The related DEs are assigned to the dataset but they are not in the form!<br>N/A for PKDL and MCL |
| H3   | DS_VL_Detailed_Annual      | VL_Lab_RDT_results_type /<br>NTD_LSH_VL_EPI_NEW_UNSI         | N/A for CL (All types) and PKDL.  |   |
| H4   | DS_VL_Detailed_Annual      | VL_Lab_RDT_tested_type                                       | name="New"<br>id="psVSPLecllyFj"<br>name="Type unspecified"<br>id="IRW4YrOtk5q"                   | VL_Lab_RDT_results_type (New + Unsp.) /<br>VL_Lab_RDT_tested_type (New + Unsp.)                   |
|      |                            | VL_Lab_RDT_results_type                                      | name="New, Positive"<br>id="jRcT6HVkb2t"<br>name="Type unspecified, Positive"<br>id="YXktM46YiXo" | N/A for CL (All types) and PKDL.  |
| H5   | DS_VL_Detailed_Annual      | VL_Lab_parasito_tested_type                                  | New<br>Relapse  | Direct exam diagnosed /<br>Total cases (C4)   |

|    |  |  |   |  |
|----|--|--|---|--|
|    | DS_CL_Detailed_Annual<br>DS_ACL/ZCL_Detailed_Monthly | CL_LAB_parasito_Suspects                             | Type unspecified  |  |
|    | DS_ACL/ZCL_Detailed_Annual                           | ACL_Lab_Parasito_Results<br>ZCL_Lab_Parasito_Results |   |  |
| H6 | DS_VL_Detailed_Annual                                | VL_LAB_parasito_result_type                          | name="New, Positive"<br>id="jRcT6HVKb2t"  | Direct exam diagnosed /<br>Direct exam diagnoses (numerator on H5)                             |
|    | DS_CL_Detailed_Annual<br>DS_ACL/ZCL_Detailed_Monthly | CL_LAB_Parasito_Results                              | name="Relapse, Positive"<br>id="QKqVJ13mGZI"  |  |
|    | DS_ACL/ZCL_Detailed_Annual                           | ACL_Lab_Parasito_Results<br>ZCL_Lab_Parasito_Results | name="Type unspecified, Positive"<br>id="YXktM46YiXo"   |  |
| H7 | DS_VL_Detailed_Annual                                | VL_LAB_clinical                                      | New Relapse<br>Type unspecified   | Clinical cases /<br>Total cases (C4)   |
|    | DS_CL_Detailed_Annual<br>DS_ACL/ZCL_Detailed_Monthly | NO DATA ELEMENT                                      |   |  |
|    | DS_ACL/ZCL_Detailed_Annual                           | NO DATA ELEMENT<br>NO DATA ELEMENT                   |   |  |
| H8 | DS_VL_Detailed_Annual                                | VL_LAB_HIVstatus_Type                                | name="New, Positive"<br>id="jRcT6HVKb2t"<br>name="Relapse, Positive"<br>id="QKqVJ13mGZI"<br>name="Type unspecified, Positive"<br>id="YXktM46YiXo" | VL_LAB_HIVstatus_Type (New Positive + Relapse Positive + Unsp. Positive) /<br>Total cases (C4) |

### 3.7 Treatment and medicines and Treatment Outcome section

#### TREATMENT AND MEDICINES

|  |  |  |
|--|--|--|
| I1   | Is treatment provided for free in the public sector? (CL / VL):    | N/A / Yes  |
| I2   | Antileishmanial medicines included in the National Medicine List:  | Amphotericin B deoxycholate, Miltefosine, Paromomycin, Sodium stibogluconate (SSG) |
| <b>INITIAL TREATMENT OUTCOME FOR NEW CASES</b> |  |  |
| I3   | Proportion of cases treated (% , # treated cases/ total cases):    | VL 98% (247 / 252) CL N/A ACL N/A ZCL N/A  |
| I4   | Initial cure rate (% , # cases initially cured /total cases):      | 96% (243 / 252) N/A N/A N/A  |
| I5   | Failure rate (% , # patients with treatment failure /total cases): | 0% (0 / 252) N/A N/A N/A   |
| I6   | Case fatality rate (% , # patients who died/ total cases):         | 2% (4 / 252) N/A N/A N/A   |

| CO DE | DataSet  | DE / Indicator  | Comments  |
|-------|--|---|---|
| I1    | DS_VL_Detailed_Annual  | VL_GEN_TxFree   | Converts codes into texts:<br>1: Yes<br>2: No<br>9: Unknown   |
|       | DS_CL_Detailed_Annual<br>DS_ACL/ZCL_Detailed_Annual  | CL_GEN_TxFree   |   |
| I2    | DS_VL_Detailed_Annual<br>DS_CL_Detailed_Annual<br>DS_ACL/ZCL_Detailed_Annual                           | Leish_GEN_EML_AmphotericinB<br>Leish_GEN_EML_LiposomalAmp<br>Leish_GEN_EML_Meglumine<br>Leish_GEN_EML_Miltefosine<br>Leish_GEN_EML_Paromomycin<br>Leish_GEN_EML_Pentamidine<br>Leish_GEN_EML_SSG              | LCPG retrieves ids and replaced by hardcodes names:<br>Amphotericin B deoxycholate<br>Liposomal amphotericin B<br>Meglumine antimoniate<br>Miltefosine<br>Paromomycin<br>Pentamidine<br>Sodium stibogluconate (SSG)   |
| I3    | DS_VL_Detailed_Annual  | VL_TREAT_completed<br>/<br>NTD_LSH_VL_EPI_NEW_UNSL  |   |
|       | DS_CL_Detailed_Annual  | CL_TREAT_completed<br>/<br>NTD_LSH_CL_EPI_NEW_UNSL  |   |
|       | DS_ACL/ZCL_Detailed_Annual   | NTD_LSH_ACL_TREAT_completed_I<br>NTD_LSH_ZCL_TREAT_completed_I<br>/<br>NTD_LSH_ACL_EPI_NEW_UNSL<br>NTD_LSH_ZCL_EPI_NEW_UNSL   |   |
| I4    | DS_VL_Detailed_Annual<br>DS_CL_Detailed_Monthly<br>DS_CL_Detailed_Annual<br>DS_ACL/ZCL_Detailed_Annual | VL_INIT_ITxO_Drug_Type<br>CL_ITxO_Tx-route<br>ACL_ITxO_Tx-drug<br>ZCL_ITxO_Tx-drug<br><br>/<br><br>NTD_LSH_VL_EPI_NEW_UNSL<br>NTD_LSH_CL_EPI_NEW_UNSL<br>NTD_LSH_ACL_EPI_NEW_UNSL<br>NTD_LSH_ZCL_EPI_NEW_UNSL | Ambisome, New, Initial Cure<br>Ambisome, Type unspecified, Initial Cure<br>Antimonials, New, Initial Cure<br>Antimonials, Type unspecified, Initial Cure<br>Meglumine Antimoniate (glucantime), New, Initial Cure<br>Meglumine Antimoniate (glucantime), Type unspecified, Initial Cure<br>Other CL drug, New, Initial Cure<br>Other CL drug, Type unspecified, Initial Cure<br>Other VL drug, New, Initial Cure<br>Other VL drug, Type unspecified, Initial Cure<br>SSG, New, Initial Cure<br>SSG + Paramomycin, New, Initial Cure<br>SSG + Paramomycin, Type unspecified, Initial Cure<br>SSG, Type unspecified, Initial Cure<br>Treatment Drug Unknown, New, Initial Cure<br>Treatment Drug Unknown, Type unspecified, Initial Cure<br>VL drug unspecified, New, Initial Cure<br>VL drug unspecified, Type unspecified, Initial Cure |
| I5    |  |   | Ambisome, New, Failure<br>Ambisome, Type unspecified, Failure<br>Antimonials, New, Failure<br>Antimonials, Type unspecified, Failure<br>Meglumine Antimoniate (glucantime), New, Failure<br>Meglumine Antimoniate (glucantime), Type unspecified, Failure<br>Other CL drug, New, Failure<br>Other CL drug, Type unspecified, Failure<br>Other VL drug, New, Failure<br>Other VL drug, Type unspecified, Failure<br>SSG, New, Failure<br>SSG + Paramomycin, New, Failure<br>SSG + Paramomycin, Type unspecified, Failure   |

|    |  |  |   |
|----|--|--|---|
|    |  |  | SSG, Type unspecified, Failure<br>Treatment Drug Unknown, New, Failure<br>Treatment Drug Unknown, Type unspecified, Failure<br>VL drug unspecified, New, FailureVL drug unspecified, Type unspecified, Failure  |
| 16 |  |  | Ambisome, New, Death<br>Ambisome, Type unspecified, Death<br>Antimonials, New, Death<br>Antimonials, Type unspecified, Death<br>Meglumine Antimoniate (glucantime), New, Death<br>Meglumine Antimoniate (glucantime), Type unspecified, Death<br>Other CL drug, New, Death<br>Other CL drug, Type unspecified, Death<br>Other VL drug, New, Death<br>Other VL drug, Type unspecified, Death<br>SSG, New, Death<br>SSG + Paramomycin, New, Death<br>SSG + Paramomycin, Type unspecified, Death<br>SSG, Type unspecified, Death<br>Treatment Drug Unknown, New, Death<br>Treatment Drug Unknown, Type unspecified, Death<br>VL drug unspecified, New, DeathVL drug unspecified, Type unspecified, Death |